Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Alzheimer's Disease

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 17 articles:
HTML format



Single Articles


    July 2021
  1. RABINOVICI GD
    Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMp2111320.
    PubMed    


  2. DUNN B, Stein P, Temple R, Cavazzoni P, et al
    An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease.
    N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMc2111960.
    PubMed    


    May 2021
  3. LEVEY AI
    Progress with Treatments for Alzheimer's Disease.
    N Engl J Med. 2021;384:1762-1763.
    PubMed    


    March 2021
  4. MINTUN MA, Lo AC, Duggan Evans C, Wessels AM, et al
    Donanemab in Early Alzheimer's Disease.
    N Engl J Med. 2021 Mar 13. doi: 10.1056/NEJMoa2100708.
    PubMed     Abstract available


    October 2020
  5. FRIED LP, Rowe JW
    Health in Aging - Past, Present, and Future.
    N Engl J Med. 2020;383:1293-1296.
    PubMed    


    June 2020
  6. INGELFINGER JR
    Kinder, Gentler Dementia-Friendly Alzheimer's Care.
    N Engl J Med. 2020;382:2487-2489.
    PubMed    


    August 2019
  7. DEEB W, Salvato B, Almeida L, Foote KD, et al
    Fornix-Region Deep Brain Stimulation-Induced Memory Flashbacks in Alzheimer's Disease.
    N Engl J Med. 2019;381:783-785.
    PubMed    


    July 2019
  8. KENNEDY ME, Egan MF
    Verubecestat for Prodromal Alzheimer's Disease. Reply.
    N Engl J Med. 2019;381:389.
    PubMed    


  9. LI S, Liu L, Selkoe D
    Verubecestat for Prodromal Alzheimer's Disease.
    N Engl J Med. 2019;381:388.
    PubMed    


    April 2019
  10. HENLEY D, Raghavan N, Sperling R, Aisen P, et al
    Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease.
    N Engl J Med. 2019;380:1483-1485.
    PubMed    


  11. EGAN MF, Kost J, Voss T, Mukai Y, et al
    Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
    N Engl J Med. 2019;380:1408-1420.
    PubMed    


  12. KNOPMAN DS
    Lowering of Amyloid-Beta by beta-Secretase Inhibitors - Some Informative Failures.
    N Engl J Med. 2019;380:1476-1478.
    PubMed    


    May 2018
  13. EGAN MF, Kost J, Tariot PN, Aisen PS, et al
    Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
    N Engl J Med. 2018;378:1691-1703.
    PubMed     Abstract available


    March 2018
  14. DEVI G
    Alzheimer's Disease in Physicians - Assessing Professional Competence and Tempering Stigma.
    N Engl J Med. 2018;378:1073-1075.
    PubMed    


    January 2018
  15. MURPHY MP
    Amyloid-Beta Solubility in the Treatment of Alzheimer's Disease.
    N Engl J Med. 2018;378:391-392.
    PubMed    


  16. HONIG LS, Vellas B, Woodward M, Boada M, et al
    Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
    N Engl J Med. 2018;378:321-330.
    PubMed     Abstract available


    May 2017
  17. SACKS CA, Avorn J, Kesselheim AS
    The Failure of Solanezumab - How the FDA Saved Taxpayers Billions.
    N Engl J Med. 2017;376:1706-1708.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: